Skip to main content
Premium Trial:

Request an Annual Quote

Affy's Decision to Shutter Mass Plant Will Cost $15M-$19M

NEW YORK (GenomeWeb News) – Affymetrix's decision to shutter its Bedford, Mass., plant will cost it between $15 million and $19 million, the company said in a filing with Securities and Exchange Commission yesterday.
 
As GenomeWeb News reported earlier this month, the company decided to shut its instrument manufacturing and development facility as part of a restructuring plan to cut costs. The facility will be consolidated with two existing plants in California.
 
Employee severance and relocation benefits are expected to cost between $8 million and $10 million. Vacating the facility, which was under lease, will cost between $5 million and $7 million.
 
Approximately $2 million will be spent on other costs, including fixed-asset write downs and equipment and inventory relocation costs.
 
These restructuring expenses will be reflected in the third cal quarter of 2006 and continue through the third quarter 2007.
 
Cash outlays incurred in connection with these restructuring activities are estimated to be in the range of $14 million to $18 million.
 
Affymetrix expects to complete the closure by third quarter of 2007.
 
As part of the shutdown, approximately 80 positions will be eliminated or transfered beginning in the fourth quarter this year and continuing into the first half of 2007, yesterday's filing reiterated.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more